OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
11
Results
Show all
Save search
Copy query
Show results for
Unknown
(11)
Publication Date
Release Date
2019
(4)
2025
(2)
2020
(2)
2021
(1)
2018
(1)
2011
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Clinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial.
Not available
S-EPMC6432893
|
biostudies-literature
Cite
Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.
Not available
S-EPMC6593785
|
biostudies-literature
Cite
Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
Not available
S-EPMC7868011
|
biostudies-literature
Cite
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
Not available
S-EPMC7756873
|
biostudies-literature
Cite
Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.
Not available
S-EPMC3127557
|
biostudies-literature
Cite
Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of Sabirnetug.
Not available
S-EPMC12504043
|
biostudies-literature
Cite
Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.
Not available
S-EPMC6693431
|
biostudies-literature
Cite
Maintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension data.
Not available
S-EPMC6477726
|
biostudies-literature
Cite
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
Not available
S-EPMC5838630
|
biostudies-literature
Cite
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Not available
S-EPMC12184067
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets